Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study

References

• Seeman E. Pathogenesis of osteoporosis. J Appl Physiol 2003; 95: 142–151
   Google Scholar
• Felson D T, Nevitt M C. The effects of estrogen on osteoarthritis. Curr Opin Rheumatol 1998; 10: 269–272
   PubMedGoogle Scholar
• Tankó L B, Karsdal M A, Christiansen C. The clinical potential of estrogen for the prevention of osteoarthritis: what is known and what needs to be done?. Women's Health 2005; 1: 125–132
   Google Scholar
• Utian W H, Shoupe D, Bachmann G, Pinkerton J V, Pickar J H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065–1075
   PubMed Web of Science ®Google Scholar
• Tan D, Haines C J, Limpaphayom K K, Holinka C F, Ausmanas M K. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia Menopause (PAM) study. Maturitas 2005; 52: 35–51
   PubMed Web of Science ®Google Scholar
• Haines C J, Xing S-M, Park K-H, Holinka C F, Ausmanas M K. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia menopause study. Maturitas 2005; 52: 264–276
   PubMed Web of Science ®Google Scholar
• Limpaphayom K K, Darmasetiawan M S, Hussain R I, Burriss S W, Holinka C F, Ausmanas M K. Differential prevalence of quality of life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia Menopause (PAM) study. Climacteric 2006; 9: 204–214
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Horsman A, Jones M, Francis R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med 1983; 309: 1405–1407
   PubMed Web of Science ®Google Scholar
• Lindsay R, Hart D M, Clark D M. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63: 759–763
   PubMed Web of Science ®Google Scholar
• Schaller S, Henriksen K, Høegh-Andersen P, et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases. How biomarkers can assist?. ASSAY Drug Development Technologies 2005; 3: 553–580
   PubMed Web of Science ®Google Scholar
• Cloos P A, Lyubimova N, Solberg H, et al. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 2004; 50: 279–289
   PubMedGoogle Scholar
• Garnero P, Gineyts E, Schaffer A V, Seaman J, Delmas P D. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum 1998; 41: 354–360
   PubMed Web of Science ®Google Scholar
• Alexandersen P, Peris P, Guanabens N, et al. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 2005; 20: 588–595
   PubMed Web of Science ®Google Scholar
• Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 1995; 41: 1439–1445
   PubMed Web of Science ®Google Scholar
• Christgau S, Garnero P, Fledelius C, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001; 29: 209–215
   PubMed Web of Science ®Google Scholar
• Blumsohn A. Bone remodeling markers: assessment of fracture risk and fracture risk reduction. Curr Osteoporos Rep 2003; 1: 91–97
   PubMedGoogle Scholar
• Eastell R, Barton I, Hannon R A, Chines A, Garnero P, Delmas P D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051–1056
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher J C, Kleerekoper M, Pickar J H. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668–2676
   PubMed Web of Science ®Google Scholar
• Reijman M, Hazes J MW, Bierma-Zeinstra S MA, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004; 50: 2471–2478
   PubMed Web of Science ®Google Scholar
• Rosenquist C, Bonde M, Fledelius C, Qvist P. A simple enzyme-linked immunosorbent assay of human osteocalcin. Clin Chem 1994; 40: 1258–1264
   PubMed Web of Science ®Google Scholar
• Oestergaard S, Chouinard L, Doyle N, et al. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Osteoarthritis Cartilage 2006; 14: 670–679
   PubMed Web of Science ®Google Scholar
• Oestergaard S, Sondergaard B C, Hoegh-Andersen P, et al. Effects of ovariectomy and estrogen therapy on collagen type II degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arth Rheum 2006; 54: 2441–2451
   PubMed Web of Science ®Google Scholar
• Bettica P, Cline G, Hart D J, Meyer J, Spector T D. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002; 46: 3178–3184
   PubMed Web of Science ®Google Scholar
• Behets C, Williams J M, Chappard D, Devogelaer J P, Manicourt D H. Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency. J Bone Miner Res 2004; 19: 1821–1826
   PubMed Web of Science ®Google Scholar
• Hayami T, Pickarski M, Wesolowski G A, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004; 50: 1193–1206
   PubMed Web of Science ®Google Scholar
• Ham K D, Carlson C S. Effects of estrogen replacement therapy on bone turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of ovariectomized cynomolgus monkeys. J Bone Miner Res 2004; 19: 823–829
   PubMed Web of Science ®Google Scholar
• Richmond R S, Carlson C S, Register T C, Shanker G, Loeser R F. Functional estrogen receptors in adult articular cartilage: estrogen replacement therapy increases chondrocyte synthesis of proteoglycans and insulin-like growth factor binding protein 2. Arthritis Rheum 2000; 43: 2081–2090
   PubMed Web of Science ®Google Scholar
• Bagger Y Z, Tankó L B, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005; 37: 425–430
   PubMed Web of Science ®Google Scholar